Vyvgart® Hytrulo
VYVGART® HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. (1)
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
![](https://vivoinfusion.com/wp-content/uploads/2024/01/Screen-Shot-2024-01-30-at-10.58.30-PM.png)
MANUFACTURER: Argenx |
CLASS: FcRn Inhibitor |
WHAT IT TREATS: Myasthenia Gravis |
PRESCRIBED BY: Neurologists |
HOW ADMINISTERED: Infusion |
FREQUENCY: Once a week for 4 weeks |
Length of infusion: 60 mins |